Auven Therapeutics (United States)

Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets. The company is focused on the healthcare industry, acquiring controlling ownership in promising therapeutic products or platforms and enhancing their value through global development programs before selling them as clinically and commercially validated products to established pharmaceutical companies. Founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund registered in the British Virgin Islands. Auven Therapeutics Development, the operating company, manages drug development from bases in Lausanne, Switzerland, Ft. Lauderdale, FL, USA and Hamilton, Bermuda.

Auven Therapeutics was founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr. Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund with its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Holdings L.P., manages drug development from its bases in Lausanne, Switzerland, Ft. Lauderdale, FL, USA and Hamilton, Bermuda. The company has built a diversified portfolio of biologic and small molecule therapeutic candidates for a wide range of therapeutic indications, addressing critical unmet medical needs in cancer, ophthalmic conditions, women's health and orphan diseases. Its investments are managed or overseen by the Auven Therapeutics Development team.

Private equity firm focused on the healthcare industry, acquiring controlling ownership in promising therapeutic products or platforms and enhancing their value through global development programs.

• KIACTA™ (eprodisate disodium)

  A novel oral treatment in development for the treatment of pulmonary sarcoidosis. Previously studied in two Phase 3 studies in AA Renal Amyloidosis.

• Cequa™

  For dry eye syndrome.

• SG2000

  For oncology.

• SG2285

  For various cancer indications.

• RX10045

  For ocular inflammation.

• ADC Therapeutics

  Developing a pipeline of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.

1. 1Auven Therapeuticsauventx.com
2. 2Auven Therapeuticsauventx.com
3. 3Auven Therapeuticsauventx.com
4. 4Auven Therapeuticsauventx.com